Regorafenib (BAY 73-4506)

Catalog No.S1178 Synonyms: Fluoro-Sorafenib

Regorafenib (BAY 73-4506) Chemical Structure

Molecular Weight(MW): 482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Targets
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B NX;3OHo5SXCxcITvd4l{KEG|c3H5 Ml[5NgKBmzYEoN88US=> NWfiblh7PDhiaB?= MYLpcohq[mm2czDj[YxtKGe{b4f0bC=> NGH6XYgzPjN{OU[wPC=>
PLC/PRF/5  NGnu[IFCeG:ydH;zbZMhSXO|YYm= MX:x5qCUPcLizszN MV[0PEBp NECxenNqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NFTk[oQzPjN{OU[wPC=>
HepG2  M1fkTWFxd3C2b4Ppd{BCe3OjeR?= M4riTVHjiJN3wrFOwG0> MU[0PEBp Mli4bY5pcWKrdIOgZ4VtdCCpcn;3eIg> NX7IT|Y2OjZ|Mkm2NFg>
HEK293 NITFfVdHfW6ldHnvckBCe3OjeR?= NYjxVYZYOC534pEJ{txO NYnsTmtQOi92L{[gbC=> MYHy[YR2[2W|IFfSVFc5KGW6cILld5Nqd25? NUTkOGhLOjV6NUiwN|I>
GEO MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLONE4xOS1{MDFOwG0> NIXUN|Q6PiCq NFvJfHlFVVOR MX3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFnIOoQzPTh|OEO5NS=>
SW48 M3PEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuwMlAyNTJyIN88US=> MUe5OkBp NYLEVZdCTE2VTx?= NH7XWHZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVOyOVg{QDN7MR?=
HT29 M3S5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHZNE4xOS1{MDFOwG0> MomyPVYhcA>? MXLEUXNQ MmrCbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mn;KNlU5Ozh|OUG=
SW480 MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHz2fIMxNjBzLUKwJO69VQ>? MkTmPVYhcA>? MX7EUXNQ NVTlNndDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVr5e4tHOjV6M{izPVE>
SW620 M3zabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVywMlAyNTJyIN88US=> M33ibFk3KGh? MYTEUXNQ NWfzfG0{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWKyOVg{QDN7MR?=
HCT116 NEC5b|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;pfVAvODFvMkCg{txO NVuxXGVCQTZiaB?= MnfqSG1UVw>? MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MnLWNlU5Ozh|OUG=
LOVO NYTuXo12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHnOHkxNjBzLUKwJO69VQ>? NUmxN4VHQTZiaB?= MXrEUXNQ Mn;6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{fGfVI2QDN6M{mx
HCT150 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLB[nUxNjBzLUKwJO69VQ>? M{TUVlk3KGh? NHjmeYxFVVOR MkHabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MoK5NlU5Ozh|OUG=
SW48-CR M{Wxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrzNE4xOS1{MDFOwG0> MWe5OkBp Ml3YSG1UVw>? NF3veWJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWWyOVg{QDN7MR?=
GEO-CR M{LDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XEXVAvODFvMkCg{txO MoDmPVYhcA>? MlHTSG1UVw>? M1vWU4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4HCe|I2QDN6M{mx
KB-31 NHXoUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnrOHBUUUN3ME21MlXDuTBwMzDuUS=> MUSyOVc2OzN4MR?=
KB-G2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DBNWlEPTB;OT6xxtExNjFibl2= NUnvdmVzOjV5NUOzOlE>
LLC-PK1 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fvWWlEPTB;NEKuNOKyOy5{IH7N M4jMU|I2PzV|M{[x
LLC-PK1/MRP2 M2Dnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvZfJlKSzVyPUiyMlTDuTJwNzDuUS=> M1;sW|I2PzV|M{[x
HEK293 NHraR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHGwOnVKSzVyPUGxMlDDuTFwMjDuUS=> MVeyOVc2OzN4MR?=
HEK293/OATP1B1 MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:1TWM2OD14LkNCtVAvOyCwTR?= NHn5S3QzPTd3M{O2NS=>
HROC18 M2f5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDmTWM2OD1zLkOg{txO MkHZNlU{ODl7MUS=
HROC24 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\DTWM2OD12Lk[g{txO NHjFUJMzPTNyOUmxOC=>
HROC43 NHLLNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2xO|ZKSzVyPUWuN{DPxE1? NGPoZpczPTNyOUmxOC=>
HROC46 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPJc2VpUUN3ME2yMlQh|ryP MViyOVMxQTlzNB?=
RJ345 M1vPO2Z2dmO2aX;uJGF{e2G7 NWDtcYoyOC53L{Wg{txO NU\3c|hNOjRiaB?= NF:3eHJFVVOR NHjwOZBqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> NUHUO5VHOjV{NUO5PVQ>
RJ348 M{jCSWZ2dmO2aX;uJGF{e2G7 NXXlSJFwOC53L{Wg{txO MYiyOEBp M3zCZ2ROW09? M1jtOolvcGmkaYTzJJRp\SClZXzsJI1q\3KjdHnvci=> MXuyOVI2Ozl7NB?=
MCF-7 MVvGeY5kfGmxbjDBd5NigQ>? NH3WOncxNjVxNTFOwG0> MWWyOEBp MkGySG1UVw>? NWi1TlNNcW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v NWfMSplHOjV{NUO5PVQ>
MDA-MB-231 NITzeYhHfW6ldHnvckBCe3OjeR?= MkXwNE42NzVizszN MoXJNlQhcA>? NYfYZ5NqTE2VTx?= NUj2N|dJcW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v MoTSNlUzPTN7OUS=
HT15 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHXZXpNOS1{MDFOwG0> M17ZSVQ5KGh? MnvibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2HId|I2ODdzMEG4
DLD1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1qze|EuOjBizszN M1LqS|Q5KGh? Mk\tbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MonmNlUxPzFyMUi=
HT-29 NGiydlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LtcFEuOjBizszN NIDpSIk1QCCq Mne2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1z3VVI2ODdzMEG4
Hct-116 NEm2bmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfhWIluOS1{MDFOwG0> M1zuTVQ5KGh? Mn7zbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2X2flI2ODdzMEG4
HT15 M4G4U2Fxd3C2b4Ppd{BCe3OjeR?= MUGxMVExKM7:TR?= MW[0PEBp M2DrNIlv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXGyOVA4OTBzOB?=
DLD1 MoDmRZBweHSxc3nzJGF{e2G7 NGrPOIcyNTFyIN88US=> MlriOFghcA>? MUHpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MoTkNlUxPzFyMUi=
HT-29 NInme|ZCeG:ydH;zbZMhSXO|YYm= MYmxMVExKM7:TR?= M{P2cVQ5KGh? M1\Gb4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3WxflI2ODdzMEG4
Hct-116 Ml3VRZBweHSxc3nzJGF{e2G7 M1GzOlEuOTBizszN MYS0PEBp NG\zVmJqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHey[20zPTB5MUCxPC=>
GBM5 NH25cXNCeG:ydH;zbZMhSXO|YYm= MlniNE426oDVMT6w5qCK|ryP NHrn[YszPCCq NVuzeWxOTE2VTx?= NIO2RY9qdnSncnHjeJMhf2m2aDDsZZBifGmwaXKgeI8hcW6mdXPlJINmdGxiZHXheIg> MU[yOFkyOTJzNR?=
GBM6 NFjGT2dCeG:ydH;zbZMhSXO|YYm= NF[wWFMxNjYkgKOxMlDjiIoQvF2= M2nnWVI1KGh? NELWbW9FVVOR M{O4VIlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> MX2yOFkyOTJzNR?=
GBM12 M2q3cGFxd3C2b4Ppd{BCe3OjeR?= Mnz4NE426oDVMT6w5qCK|ryP M17ofFI1KGh? M4HWfmROW09? M3XWUYlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> M2[xSVI1QTFzMkG1
GBM14  NGPwS5ZCeG:ydH;zbZMhSXO|YYm= NVvNfXpxOC534pETNU4x6oDLzszN NFXIZ4MzPCCq NH7RdIZFVVOR M3TRZYlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> MnTjNlQ6OTF{MUW=
Hep3B M4LvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorWNgKBmzJwNdMg{txO NYHN[JFDOjRxNEivO|IhcA>? M3vFW4lvcGmkaYTzJINmdGxiZ4Lve5Rp NFPGNlUzPDh6NUi5NC=>
PLC/PRF/5  NVLpc3p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:4cVNsOeLCk{KuOeKh|ryP NW\MO3dCOjRxNEivO|IhcA>? NF61PJBqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MXuyOFg5PTh7MB?=
HepG2  MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq0Rm0y6oDVMj61xsDPxE1? MWqyOE81QC95MjDo NH;oZY1qdmirYnn0d{Bk\WyuIHfyc5d1cA>? MYeyOFg5PTh7MB?=
HCT116  MWDGeY5kfGmxbjDBd5NigQ>? M3uyPFExNzJyL{SwJO69VQ>? NY\EUZpUOjRiaB?= M{S3e4lv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDtVm5CKGW6cILld5Nqd25iaX6gZUBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NFi0[nozPDd4M{[xNS=>
Lim2405 NUfPfmdXTnWwY4Tpc44hSXO|YYm= NXHXcpZVPDBizszN MkLXNlQhcA>? NWPBb3Q3cW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| M2jOZ|I1PzZ|NkGx
LoVo NXvwemhzTnWwY4Tpc44hSXO|YYm= MXG0NEDPxE1? M4DCTVI1KGh? NV3MfoNpcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| M1XjSlI1PzZ|NkGx
Lim1215 M1XGZmZ2dmO2aX;uJGF{e2G7 M1qzflQxKM7:TR?= M2jET|I1KGh? NFL2eWRqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NV3tNGNtOjR5NkO2NVE>
SW48 MYjGeY5kfGmxbjDBd5NigQ>? MY[0NEDPxE1? M{\hOVI1KGh? NFXEXIFqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NI\1OoYzPDd4M{[xNS=>
RKO  M1PwVmZ2dmO2aX;uJGF{e2G7 NUXpV2dVPDBizszN MonaNlQhcA>? MX;pcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NIS2cJQzPDd4M{[xNS=>
SW837 NV24S5p5TnWwY4Tpc44hSXO|YYm= NGT2flk1OCEQvF2= NYqy[201OjRiaB?= M3fLVIlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? MUeyOFc3OzZzMR?=
SW1463 MlywSpVv[3Srb36gRZN{[Xl? MYG0NEDPxE1? M4jsVVI1KGh? M3jK[4lv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M1;QSVI1PzZ|NkGx
SW480 M2m5XWZ2dmO2aX;uJGF{e2G7 MljCOFAh|ryP NXXwWHlCOjRiaB?= MmXkbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NEfuS3MzPDd4M{[xNS=>
Vaco432 Mn65SpVv[3Srb36gRZN{[Xl? MWO0NEDPxE1? M2D2flI1KGh? NYrLT3FqcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MVyyOFc3OzZzMR?=
Vaco400 MkDmSpVv[3Srb36gRZN{[Xl? Ml7JOFAh|ryP MnPJNlQhcA>? M3PUbIlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? Mnv6NlQ4PjN4MUG=
DLD1 MnjDSpVv[3Srb36gRZN{[Xl? NHfR[201OCEQvF2= M3vIeVI1KGh? NU\WWVA1cW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| M1X1eVI1PzZ|NkGx
HT29  Mn3QSpVv[3Srb36gRZN{[Xl? NXjFeFlrPDBizszN M1XYWVI1KGh? NH;oc29qdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MmT2NlQ4PjN4MUG=
PLC/PRF/5  NYjGfoZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHztSWoy6oDVNdM1US=> NWDaV5FQOjRxNEivO|IhcA>? NVfvSphTcW6qaXLpeJMh[2WubDDndo94fGh? NHfCblgzOzF4OUG0PC=>
HepG2 NHLo[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfQWHRpOeLCk{ZCuW0> M1;hVFI1NzR6L{eyJIg> NWnlVm0{cW6qaXLpeJMh[2WubDDndo94fGh? NH:2doczOzF4OUG0PC=>
Hep3B  NEPhUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7QO5ky6oDVNdM1US=> NGLLXFAzPC92OD:3NkBp MUfpcohq[mm2czDj[YxtKGe{b4f0bC=> M3rvVlI{OTZ7MUS4

... Click to View More Cell Line Experimental Data

In vivo Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

Protocol

Kinase Assay:[1]
+ Expand

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research:[1]
+ Expand
  • Cell lines: GIST 882 and TT cells
  • Concentrations: 5 nM-10 μM
  • Incubation Time: 96 hours
  • Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • Formulation: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (200.9 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.82
Formula

C21H15ClF4N4O3

CAS No. 755037-03-7
Storage powder
in solvent
Synonyms Fluoro-Sorafenib

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID